Visual Impairment in Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

Update Item Information
Identifier 20190319_nanos_sciplatform3_08_slides
Title Visual Impairment in Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Creator Timothy McCulley; Jinglan Pei; Paris Sidiropoulos; Christine Birchwood; Jennie Best; John Stone; Sebastian Unizony
Affiliation (TM) The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; (JP) (PS) (CB) (JB) Genentech, Inc., South San Francisco, California; (JS) (SU) Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, Massachusetts
Subject Vascular Disorders
Description The GiACTA trial demonstrated the efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) [1]. However, the effectiveness of TCZ for prevention of specific GCA-related visual manifestations is currently unknown. The incidence of GCA-related visual manifestations was analyzed in patients treated with TCZ in a real-world setting.
Date 2019-03
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2019 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2019: Scientific Platform III
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2019. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6090s4x
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Setname ehsl_novel_nam
ID 1455040
Reference URL https://collections.lib.utah.edu/ark:/87278/s6090s4x
Back to Search Results